The BIN1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal knockout cell population targeting the BIN1 gene in the human A-549 cell line. This pool of gene-edited cells provides a loss-of-function model for investigating the tumor suppressor functions of BIN1, including its roles in endocytosis, apoptosis, and cell cycle regulation. By disrupting BIN1 expression, researchers can explore the molecular consequences of its absence in a lung adenocarcinoma background.
The parental A-549 cell line is an adherent epithelial line from a 58-year-old male lung adenocarcinoma patient. Widely used for lung cancer biology, drug response, and signaling pathway studies, A-549 cells provide a clinically relevant model for non-small cell lung cancer research.
BIN1 is a multifunctional adaptor protein that suppresses tumors by directly inhibiting MYC oncoprotein, enforcing cell cycle arrest. It is also integral to clathrin-mediated endocytosis, forming a complex with amphiphysin and dynamin 2 to drive membrane curvature and vesicle scission. This endocytic role impacts cell surface receptor trafficking and actin dynamics. BIN1 expression is repressed by MYC, creating a feedback loop, and is regulated by E2F1. Downstream, it targets RIN1 and interacts with clathrin heavy chain and synaptojanin 1 for vesicle recycling.
In the A-549 model, BIN1 loss via polyclonal knockout enables dissection of endocytosis-oncogenic signaling crosstalk. Disrupted MYC inhibition may enhance proliferation, migration, and invasion. Impaired clathrin-mediated endocytosis can alter receptor tyrosine kinase internalization, affecting downstream pathways. This polyclonal pool reflects heterogeneous edits, providing a robust system to study dominant BIN1 deficiency effects while avoiding clonal artifacts. These cells are valuable for investigating BIN1??s role in lung adenocarcinoma progression and screening therapeutics targeting MYC-driven cancers or endocytic pathways.
Researchers can use these cells for western blotting and RT-qPCR to confirm BIN1 disruption and assess downstream targets. Immunofluorescence and endocytosis assays reveal membrane trafficking changes. Apoptosis assays and flow cytometry quantify cell death and cycle alterations; migration/invasion assays assess metastatic potential; co-immunoprecipitation probes BIN1 interactors. These applications establish the BIN1 Knockout A-549 Cells as a versatile tool for lung adenocarcinoma research, drug screening, and endocytosis studies. For more information, contact Ascent Research.
